Press-release for stocks for LLY

Prices are updated after-hours

Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

symbols : LLY crawled time : 14:30

save search

Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | $13.15 -0.61% 0.38% 1.7K

|

Health Technology

| -8.3% | O: 0.21% H: 0.97% C: 0.7%
NVS | News | $93.08 -0.13% -0.04% 670

|

Health Technology

| -5.15% | O: 0.05% H: 0.14% C: -0.93%
JNJ | News | $144.77 0.22% 0.4% 130K

|

Health Technology

| -9.96% | O: -1.58% H: 0.0% C: 0.0%
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| -1.31% | O: -0.7% H: 0.73% C: -0.16%
ABBV | $164.25 1.05% 0.26% 3M

|

Health Technology

| -9.09% | O: -0.07% H: 0.0% C: 0.0%
SNY | News | $46.11 0.68% 0.7% 66K

|

Health Technology

| -4.79% | O: -0.02% H: 0.0% C: 0.0%
REGN | $901.19 0.79% 0.78% 0

|

Health Technology

| -6.03% | O: -0.27% H: 1.26% C: 0.84%
AMGN | $264.07 -0.59% -0.59% 350

|

Health Technology

| -1.7% | O: 0.2% H: 1.14% C: -1.18%
antibody therapeutics market

Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
Published: 2024-03-14 (Crawled : 14:30) - biospace.com/
AMLX | $2.0 -0.5% -1.01% 1.1K

|

| -41.57% | O: -1.45% H: 0.04% C: -6.49%
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| -0.93% | O: 0.94% H: 0.4% C: -0.55%
pharmaceuticals

Philip Johnson to Retire as Lilly Treasurer
Published: 2024-02-09 (Crawled : 14:30) - prnewswire.com
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 2.05% | O: -0.02% H: 1.39% C: 0.63%

FDA Roundup: December 5, 2023
Published: 2023-12-05 (Crawled : 14:30) - fda.gov
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 28.8% | O: 0.99% H: 0.0% C: 0.0%
fda

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
Published: 2023-12-04 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 26.39% | O: -1.96% H: 0.0% C: 0.0%
biopharma acquire

The Top 12 Biopharma Companies Hiring Now
Published: 2023-09-13 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 25.27% | O: -0.77% H: 0.0% C: 0.0%
companies biopharma

Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference
Published: 2023-09-05 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 35.17% | O: 0.68% H: 0.48% C: -0.19%
LGND | News | $78.87 -1.31% -1.25% 29

|

Health Technology

| 18.53% | O: -0.86% H: 0.0% C: -3.7%
conference breast presentation cancer pharmaceuticals research

Entos Pharmaceuticals Announces Senior Leadership Appointments to Expand Executive Team and Accelerate Growth
Published: 2022-03-03 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 200.74% | O: 2.08% H: 1.86% C: 1.5%
LJPC | $6.22 0.0%

|

Health Technology

| 47.51% | O: 1.9% H: 1.63% C: -2.33%
als ces cel growth

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline
Published: 2022-03-01 (Crawled : 14:30) - ir.pulmatrix.com
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 206.93% | O: 1.26% H: 0.0% C: 0.0%
PULM | $2.09 -1.42% 1.87% 0

|

Health Technology

| 577.03% | O: 1843.63% H: 2.17% C: -4.67%
matrix expansion

Lilly Pumps $700M into Boston-Based RNA Therapeutics Facility
Published: 2022-02-22 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 212.42% | O: -0.46% H: 0.69% C: -0.03%
therapeutics

Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 205.71% | O: 0.0% H: 0.0% C: -1.88%
VERU | $1.16 -7.57% -7.73% 2.5M

|

Health Technology

| -81.53% | O: -0.96% H: 0.88% C: -3.38%
prostate cancer symposium state phase 1b presentation asco phase 1 cancer sabizabulin phase 2b

Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
Published: 2022-02-14 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 213.47% | O: -2.3% H: 1.23% C: 0.29%
VERU | $1.16 -7.57% -7.73% 2.5M

|

Health Technology

| -81.76% | O: -0.47% H: 5.06% C: -4.11%
covid-19 covid report phase 3 sabizabulin

180 Degree Capital Corp. Portfolio Company, D-Wave Systems, Inc., Announces Intent to Become a Public Company Through a Merger With DPCM Capital, Inc. and Provides an Update on Legacy Private Portfolio Monetization Efforts
Published: 2022-02-08 (Crawled : 14:30) - globenewswire.com
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 208.97% | O: -0.45% H: 0.0% C: 0.0%
TURN | $3.98 20

|

| -44.72% | O: 0.97% H: 8.67% C: 5.98%
ces system one merge

Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial
Published: 2022-02-01 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 207.96% | O: 1.37% H: 0.0% C: 0.0%
VERU | $1.16 -7.57% -7.73% 2.5M

|

Health Technology

| -77.69% | O: 2.21% H: 4.99% C: 4.05%
verzenio trial collaboration phase 3

NCCN Announces Funding for Lung and Thyroid Cancer Quality Projects, in Collaboration with Lilly
Published: 2022-01-24 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 203.43% | O: -1.97% H: 0.5% C: -0.88%
funding collaboration cancer

RION Appoints Alisa Lask as Chief Commercial Officer
Published: 2022-01-14 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 195.58% | O: -1.46% H: 0.0% C: 0.0%
NEPH | $1.99 -1.97% 1.94% 0

|

Health Technology

| -63.15% | O: 0.19% H: 0.0% C: -2.96%
CLGN | $5.24 1.52% 1.5% 0

|

Health Technology

| -56.88% | O: 4.18% H: 0.0% C: 0.0%
commercialization

Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia
Published: 2021-12-21 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 184.94% | O: 0.2% H: 0.74% C: 0.33%
RIGL | $1.11 -2.63% -2.24% 220

|

Health Technology

| -58.43% | O: 2.25% H: 0.37% C: -0.73%
treatment trial chronic immune phase 3

Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
LLY | News | $750.77 0.54% 0.15% 8.3K

|

Health Technology

| 209.43% | O: 1.27% H: 0.0% C: 0.0%
NKTR | News | $1.35 -9.4% -10.78% 5.9K

|

Health Technology

| -89.29% | O: -3.33% H: 0.0% C: 0.0%
nktr-255 ema car-t therapeutics therapy

Gainers vs Losers

43%

57%

Top 10 Gainers

UK | $2.3 6.48% 6.2K

|

UAL | News | $51.24 5.13% 3.5M

|

UAVS | $0.655 2.65% 5.5K

|

Electronic Technology

UNH | $491.01 2.51% 470K

|

Health Services

UUUU | $5.885 2.17% 180K

|

Non-Energy Minerals

TTEC M | $7.975 1.08% 17

|

Commercial Services

URBN | $37.445 1.01% 28K

|

URI | $642.29 0.95% 6.6K

|

UNM A | $50.575 0.83% 14K

|

UNIT | $5.34 0.76% 17K

|

Your saved searches

Save your searches and get alerts when important news are released.